Endoscopy:重症急性坏死性胰腺炎患者是否应该预防性使用胰管支架置入术?

2020-09-26 MedSci原创 MedSci原创

在急性坏死性胰腺炎(ANP)的患者常见胰管破坏。在这项研究中,我们测试了预防性胰管支架(PPDS)在ANP中的可行性和安全性,并将PPDS与保守治疗进行了比较,研究结果已在线发表于Endoscopy。

在急性坏死性胰腺炎(ANP)的患者常见胰管破坏。在这项研究中,我们测试了预防性胰管支架(PPDS)在ANP中的可行性和安全性,并将PPDS与保守治疗进行了比较,研究结果已在线发表于Endoscopy。

研究人员前瞻性地纳入了2011年2月至2015年7月被诊断为ANP的患者(年龄18 - 75岁)。这些患者在两个三级中心前瞻性地随机接受PPDS或保守治疗。随机化后尽快进行PPDS。

 

结果,关于PPDS组胰腺坏死的意外感染的担忧促使研究人员进行了中期分析,证实风险高度上升。因此,该试验因伦理原因被提前终止。在PPDS组的11例患者中,所有胰管置入成功的患者(5/5,100%)均出现感染,而保守治疗组13例患者中只有3例(23.1%)出现感染(P=0.01)。分析显示,胰管插管的成功率为63.6%,胰管支架置入的成功率为45.5%,放置支架桥接坏死的成功率为18.2%。插管和支架植入失败的原因是十二指肠水肿和胰管狭窄。

综上所述,该研究结果表明,ANP中的PPDS与不可接受的高胰腺坏死感染风险有关。此外,由于十二指肠水肿和胰管狭窄,该手术在技术上具有挑战性。

 

原始出处:

 

Heikki KarjulaPalle Nordblad Schmidt, et al., Prophylactic pancreatic duct stenting in severe acute necrotizing pancreatitis: a prospective randomized study. Endoscopy. 2019 Nov;51(11):1027-1034. doi: 10.1055/a-0865-1960. 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=915810, encodeId=0085915810bb, content=👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5d42482870, createdName=12460f22m82暂无昵称, createdTime=Tue Jan 12 09:54:30 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766706, encodeId=f4841e66706f5, content=<a href='/topic/show?id=fc89e965910' target=_blank style='color:#2F92EE;'>#置入术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79659, encryptionId=fc89e965910, topicName=置入术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bd637855499, createdName=小小小向日葵, createdTime=Tue Aug 17 15:07:01 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034840, encodeId=7d9220348400d, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Fri Jun 18 03:07:01 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362992, encodeId=2fbc1362992a0, content=<a href='/topic/show?id=b723414321c' target=_blank style='color:#2F92EE;'>#坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41432, encryptionId=b723414321c, topicName=坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Mon Sep 28 10:07:01 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495884, encodeId=8b521495884c5, content=<a href='/topic/show?id=3f696e7069' target=_blank style='color:#2F92EE;'>#endoscopy#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6770, encryptionId=3f696e7069, topicName=endoscopy)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4a39226300, createdName=liuxiaona, createdTime=Mon Sep 28 10:07:01 CST 2020, time=2020-09-28, status=1, ipAttribution=)]
    2021-01-12 12460f22m82暂无昵称

    👍

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=915810, encodeId=0085915810bb, content=👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5d42482870, createdName=12460f22m82暂无昵称, createdTime=Tue Jan 12 09:54:30 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766706, encodeId=f4841e66706f5, content=<a href='/topic/show?id=fc89e965910' target=_blank style='color:#2F92EE;'>#置入术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79659, encryptionId=fc89e965910, topicName=置入术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bd637855499, createdName=小小小向日葵, createdTime=Tue Aug 17 15:07:01 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034840, encodeId=7d9220348400d, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Fri Jun 18 03:07:01 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362992, encodeId=2fbc1362992a0, content=<a href='/topic/show?id=b723414321c' target=_blank style='color:#2F92EE;'>#坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41432, encryptionId=b723414321c, topicName=坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Mon Sep 28 10:07:01 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495884, encodeId=8b521495884c5, content=<a href='/topic/show?id=3f696e7069' target=_blank style='color:#2F92EE;'>#endoscopy#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6770, encryptionId=3f696e7069, topicName=endoscopy)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4a39226300, createdName=liuxiaona, createdTime=Mon Sep 28 10:07:01 CST 2020, time=2020-09-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=915810, encodeId=0085915810bb, content=👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5d42482870, createdName=12460f22m82暂无昵称, createdTime=Tue Jan 12 09:54:30 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766706, encodeId=f4841e66706f5, content=<a href='/topic/show?id=fc89e965910' target=_blank style='color:#2F92EE;'>#置入术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79659, encryptionId=fc89e965910, topicName=置入术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bd637855499, createdName=小小小向日葵, createdTime=Tue Aug 17 15:07:01 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034840, encodeId=7d9220348400d, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Fri Jun 18 03:07:01 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362992, encodeId=2fbc1362992a0, content=<a href='/topic/show?id=b723414321c' target=_blank style='color:#2F92EE;'>#坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41432, encryptionId=b723414321c, topicName=坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Mon Sep 28 10:07:01 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495884, encodeId=8b521495884c5, content=<a href='/topic/show?id=3f696e7069' target=_blank style='color:#2F92EE;'>#endoscopy#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6770, encryptionId=3f696e7069, topicName=endoscopy)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4a39226300, createdName=liuxiaona, createdTime=Mon Sep 28 10:07:01 CST 2020, time=2020-09-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=915810, encodeId=0085915810bb, content=👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5d42482870, createdName=12460f22m82暂无昵称, createdTime=Tue Jan 12 09:54:30 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766706, encodeId=f4841e66706f5, content=<a href='/topic/show?id=fc89e965910' target=_blank style='color:#2F92EE;'>#置入术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79659, encryptionId=fc89e965910, topicName=置入术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bd637855499, createdName=小小小向日葵, createdTime=Tue Aug 17 15:07:01 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034840, encodeId=7d9220348400d, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Fri Jun 18 03:07:01 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362992, encodeId=2fbc1362992a0, content=<a href='/topic/show?id=b723414321c' target=_blank style='color:#2F92EE;'>#坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41432, encryptionId=b723414321c, topicName=坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Mon Sep 28 10:07:01 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495884, encodeId=8b521495884c5, content=<a href='/topic/show?id=3f696e7069' target=_blank style='color:#2F92EE;'>#endoscopy#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6770, encryptionId=3f696e7069, topicName=endoscopy)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4a39226300, createdName=liuxiaona, createdTime=Mon Sep 28 10:07:01 CST 2020, time=2020-09-28, status=1, ipAttribution=)]
    2020-09-28 millore
  5. [GetPortalCommentsPageByObjectIdResponse(id=915810, encodeId=0085915810bb, content=👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5d42482870, createdName=12460f22m82暂无昵称, createdTime=Tue Jan 12 09:54:30 CST 2021, time=2021-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1766706, encodeId=f4841e66706f5, content=<a href='/topic/show?id=fc89e965910' target=_blank style='color:#2F92EE;'>#置入术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79659, encryptionId=fc89e965910, topicName=置入术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bd637855499, createdName=小小小向日葵, createdTime=Tue Aug 17 15:07:01 CST 2021, time=2021-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2034840, encodeId=7d9220348400d, content=<a href='/topic/show?id=69c910030635' target=_blank style='color:#2F92EE;'>#预防性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100306, encryptionId=69c910030635, topicName=预防性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Fri Jun 18 03:07:01 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362992, encodeId=2fbc1362992a0, content=<a href='/topic/show?id=b723414321c' target=_blank style='color:#2F92EE;'>#坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41432, encryptionId=b723414321c, topicName=坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Mon Sep 28 10:07:01 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495884, encodeId=8b521495884c5, content=<a href='/topic/show?id=3f696e7069' target=_blank style='color:#2F92EE;'>#endoscopy#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6770, encryptionId=3f696e7069, topicName=endoscopy)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4a39226300, createdName=liuxiaona, createdTime=Mon Sep 28 10:07:01 CST 2020, time=2020-09-28, status=1, ipAttribution=)]